SG/PUT/ASTRAZENECA/12000/0.1/20.09.24 Stock

SG/PUT/ASTRAZENECA/12000/0.1/20.09.24 Share Price

DE000SW9N9R1

Real-time Boerse Frankfurt Warrants 01:20:41 27/06/2024 pm IST
0.4 ^EUR	+11.11%

Current month	-36.84%
1 month	-32.08%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart SG/PUT/ASTRAZENECA/12000/0.1/20.09.24

Latest news about ASTRAZENECA PLC

European Equities Close Lower in Wednesday Trading	26/06	MT
Astrazeneca - IMFINZI demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial	26/06	AQ
Astrazeneca - Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer	26/06	AQ
ASTRAZENECA : Deutsche Bank sticks Neutral	26/06	ZD

More news

Quotes 5-day view

Date	Price	Change
27/24/27	0.4	+11.11%
26/24/26	0.36	0.00%
25/24/25	0.36	-5.26%
24/24/24	0.38	-2.56%
21/24/21	0.39	-7.14%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 01:20 pm IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	ASTRAZENECA PLC
Issuer	Société Générale
WKN	SW9N9R
ISIN	DE000SW9N9R1
Date issued	29/04/2024
Strike	12,000 p
Maturity	20/09/2024 (86 Days)
Parity	10 : 1
Emission price	0.75 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.74 €
Lowest since issue	0.34 €
Spread	0.01 €
Spread %	2.44%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company